TerminatedNot Applicable

Viral Conjunctivitis Treatment Study

Stopped: COVID-19 Pandemic

United States11 participantsStarted 2018-11-14

Plain-language summary

The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid) in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral Conjunctivitis compared with artificial tears.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients presenting to the Bascom Palmer Eye Institute * Clinical diagnosis of viral conjunctivitis * Symptoms less than 1 week duration Exclusion Criteria: * history of allergic conjunctivitis * history of herpetic eye disease * concurrent diagnosis of bacterial conjunctivitis (based off microbiology plating) * Immunocompromised / Immunosuppressed patients * Patients with HIV * pregnant women * prisoners * adults who are unable to provide consent

What they're measuring

Number of Participants With Clinical Resolution of Viral Conjunctivitis

Timeframe: Up to 8 days

Trial details

NCT IDNCT03861728

SponsorUniversity of Miami

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-02-08

Results submitted2021-11-29

View on ClinicalTrials.gov More Viral Conjunctivitis trials